"Das Luzerner Kantonsspital (LUKS) ist das grösste Zentrumsspital der Schweiz. Es umfasst die Standorte Luzern, Sursee und Wolhusen sowie die Luzerner Höhenklinik Montana. Rund 7'000 Mitarbeitende sorgen rund um die Uhr für das Wohl der Patientinnen und Patienten. Das LUKS verfügt über 870 Akutbetten und versorgt ein Einzugsgebiet mit rund 700'000 Einwohnern. Es behandelt jährlich über 43'000 stationäre Patientinnen und Patienten und zählt über 600'000 ambulante Patientenkontakte. Die Kliniken und Institute des LUKS bieten medizinische Leistungen von höchster Qualität."

During the past decade, Kantonsspital Luzern conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 3 clinical trials were completed, i.e. on average, 37.5% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 1 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kantonsspital Luzern" #1 sponsor was "Loxo Oncology, Inc." with 3 trials, followed by "Pfizer" with 2 trials sponsored, "SIS Medical AG" with 2 trials sponsored, "Celgene" with 1 trials sponsored and "Eli Lilly and Company" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kantonsspital Luzern" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator and "Novartis Pharma AG, Basel, Switzerland" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Kantonsspital Luzern" are "Cardiovascular Disease" (2 trials), "Colon Cancer" (2 trials), "Coronary Artery Disease" (2 trials), "Medullary Thyroid Cancer" (2 trials) and "Angina" (1 trials). Many other conditions were trialed in "Kantonsspital Luzern" in a lesser frequency.

Most popular intervention types in "Kantonsspital Luzern" are "Drug" (8 trials), "Other" (3 trials), "Device" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "bococizumab (PF-04950615)" (2 trials), "Absorb BVS implantation." (1 trials), "Acalabrutinib" (1 trials) and "BVS Absorb implantation." (1 trials). Other intervention names were less common.

The vast majority of trials in "Kantonsspital Luzern" are 10 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Kantonsspital Luzern". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Kantonsspital Luzern, 1 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Kantonsspital Luzern, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".